相关实验视频

Updated: May 6, 2026

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

化胺5-碳酸胺作为MERTK化-18-PET-放射性联体开发的潜在工具

Ramesh Mudududdla¹, Siu Wai Wong¹, Nghi Nguyen¹

¹Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University Parkville Victoria 3052 Australia jbaell29@gmail.com.

RSC medicinal chemistry

|December 8, 2025

概括

研究人员开发了新的化化合物,以描绘微质在多发性硬化症 (MS) 中的保护作用. 这些强大的MERTK连接体可能会导致用于早期MS检测和治疗监测的PET标记物.

科学领域:

神经科学是一个神经科学.
放射化学放射化学是指辐射化学.
免疫学免疫学免疫学

背景情况:

微质在神经保护和修复中起着至关重要的作用,特别是在多发性硬化症 (MS) 等疾病中.
MER 氨酸激酶 (MERTK) 是微质的抗炎和免疫抑制表型的关键标记物.
开发成像工具来区分微质反应对于MS诊断和管理至关重要.

研究的目的:

发现新的F-射线追踪器用于成像MS的保护性微质表型.
为了确定强效和选择性的MERTK配体用于正电子发射断层扫描 (PET) 标记器的开发.

主要方法:

基于MERTK连接体的化胺-5-碳胺衍生物的合成.
使用基于细胞的试验评估MERTK抑制功效.
对非位激酶 (如AXL,TYRO3和FLT3.3) 的选择性评估.

主要成果:

发现了几种强效和选择性的化MERTK连接体.
化合物在与*in vivo*成像相关的基于细胞的测定中显示出有前途的抑制活性.
在关键的非目标激酶上实现选择性,减少潜在的混信号.

结论:

这些已识别的化合物是开发新型PET标记剂的有希望的候选物.
这些标记物可以使MS患者的保护性微质表型的非侵入性成像.
这项研究为改善早期检测和监测MS进展和治疗反应铺平了道路.

更多相关视频

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...